Paroxetine is sold under the trade name Paxil, and was approved by the FDA in 1992. Paroxetine is also considered one of the most challenging SSRIs to discontinue and why so many people start our holistic program to get off Paroxetine and escape Paroxetine dependence. In addition to the high rate of Paroxetine discontinuation syndrome, Paroxetine was also associated with a dramatic increase in the rate of breast cancer for woman who were on Paxil for a 4 year period or longer.  Suddenly stopping Paroxetine can lead to a severe Paroxetine discontinuation syndrome with Paroxetine withdrawal symptoms that can include anxiety, insomnia, depression headaches, chills, nausea vomiting and diarrhea. Please do not attempt getting off Paroxetine on your own, let our prescription drug experts help you.*
Below is information about Paroxetine, Paroxetine withdrawal, and getting off Paroxetine naturally.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
START OUR PAROXETINE WITHDRAWAL PROGRAM
LEARN MORE ABOUT OUR IN-HOME WITHDRAWAL PROGRAM
TALK TO A REAL PERSON 866-605-2333 (toll-free)
WHAT IS PAROXETINE WITHDRAWAL LIKE?
PAROXETINE WITHDRAWAL HELP - GETTING OFF PAROXETINE NATURALLY
For over 17 years, Point of Return 501(c)3 nonprofit, has helped people all over the world with safely getting off Paroxetine. Our Paroxetine withdrawal tapering program is a proven holistic approach that allows you to step down on Paroxetine while minimizing Paroxetine withdrawal symptoms with proven, specifically designed nutraceuticals that will not interact, yet provide needed relief. Your Paroxetine tapering program is done under the guidance of Our Team, Your Physician, and Pharmacist and allows you to taper off Paroxetine in smaller reduction amounts that are not produced by the pharmaceutical companies. Our Pre-Taper is for Paroxetine symptom relief - you will not wean Paroxetine until you feel better. This is where our advanced nutraceuticals are critical to the Paroxetine withdrawal process. We understand the unique demands placed on the body and nervous system by Paroxetine. Point of Return provides healthy, proven, Drug-Free strategies to help ease Paroxetine withdrawal symptoms while supporting your well being.*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our innovative approach to antidepressant tapering encompasses a holistic method to empower you on your path to recovery. No need to go through Paroxetine withdrawal alone, work with our Prescription Drug Experts.*
PAROXETINE WITHDRAWAL SYMPTOMS MAY INCLUDE
- balance issues
- blurred vision
- brain zaps
- concentration impairment
- crying spells
- electric shock sensations
- highly emotional
- impaired speech
- jumpy nerves
- lack of coordination
- migraine headaches / increased headaches
- over-reacting to situations
- repetitive thoughts or songs
- sensory & sleep disturbances
- severe internal restlessness (akathisia)
- stomach cramps
- tremors, tinnitus (ear ringing or buzzing)
- tingling sensations
- troubling thoughts
- visual hallucinations / illusions
- vivid dreams
- speech or visual changes
- worsened depression 
IMAGINE BEING FREE OF PAROXETINE DEPENDENCY
✔ Proven Program completed In-Home
✔ Slowly Wean Off Paroxetine
✔ All-Natural Nutraceuticals to help ease symptoms and make Paroxetine Withdrawal easier*
✔ Professional information and support to empower you
✔ Free Mentoring on our 24/7 private Discussion Board
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program (USA & Canada Only)
PAROXETINE WITHDRAWAL TIMELINE
Many will feel a reduction in even one dose of Paroxetine and others within 24-48 hours. Paroxetine Withdrawal symptoms can peak within 4-5 days of a reduction and continue to escalate.  Paroxetine has shown the most likely of any SSRI to be associated with severe depressive and antidepressant withdrawal symptoms. Point of Return understands the hazards of Paroxetine Withdrawal and implement both a slow taper approach combined with specially formulated nutraceuticals that have made our holistic approach to Paroxetine withdrawal successful for 17 years. Contact us for help with getting off Paroxetine.*
PAROXETINE WITHDRAWAL SUCCESS STORIES
I give the glory to God for directing my path to Alesandra and to Point of Return! More...
Debbie (Paroxetine Withdrawal Success Story)
Thank you, again, for answering my constant barrage of questions, for being there when I was scared, for celebrating with me. And, most of all, for helping me get my life back. More...
Laurie (Paroxetine Withdrawal Success Story)
I still can't believe it. After 15 years I am finally med free thanks to the Point of Return team!!!!! More...
Dan (Paroxetine Withdrawal Success Story)
An Australian review of Paroxetine uncovered evidence that the drug's manufacturer downplayed the deadly side effects and exaggerated its benefits. The study was published in the British Medical Journal and showed that Paroxetine was not effective and safe for young people as the pharmaceutical company claimed.
Paroxetine is one of the most potent of the SSRIs (Selective Serotonin Reuptake Inhibitors) and has shown a high incidence of dependence. Paroxetine is associated with a high incidence and severity of withdrawal symptoms (discontinuation syndrome) and therefore it is recommended to taper gradually to help minimize the discomfort.
Paxil was derived from Paroxetine, which was originally developed by Ferrosan, a Danish company who began researching the compound in the 1960s. By the 1970s Ferroson developed a paroxetine formula, called the ‘Buus-Lassen compound’, and patented it in the United States in 1977. SmithKline Pharmaceuticals bought the rights and research in 1980, made revisions and patented the new paroxetine formula in 1986.
The clinical trials were performed in under-developed countries and the results were called less-than-desired by industry insiders. SmithKline was able to compile sufficient positive data to obtain an FDA approval for the brand name Paxil in 1992 and by 2007 was the 5th most prescribed antidepressant drug in the United States.
The BBC reported in 2001 that the World Health Organization had ranked Paroxetine as the most difficult antidepressant to withdraw from. GlaxoSmithKline marketed the drug extensively as “non-habit forming” and yet this was proven to be false by numerous experts. More recently FDA scientists and other research institutions discovered that taking Paxil during pregnancy could dramatically increase the risk of serious birth defects including heart, lung, brain and spine defects, skull deformities, club foot, and abdominal defects. The FDA issued a Public Health Advisory for the use of Paxil during pregnancy and deemed a Category D pregnancy risk was required, meaning that there is clear risk to a human fetus when Paxil is taken during gestation. This category change, Public Health Advisory and notice to physicians all came after the drug had been on the market for more than 10 years.
PAROXETINE SIDE EFFECTS AND ADVERSE REACTIONS
PAROXETINE SIDE EFFECTS MAY INCLUDE:
Abnormal dreams, abnormal ejaculation or orgasm, anxiety, appetite loss, blurred vision, chills, constipation, diarrhea, dizziness, dry mouth, frequent urination, flushing, gas, headache, impotence, infection, insomnia, muscle tension, nausea, nervousness, rash, sleepiness, sweating, tingling feeling, tremor, upset stomach, vomiting, weakness, yawning, abnormal taste, abnormal thinking, agitation, chest pain, confusion, decreased sex drive, depression, dilated pupils, dizziness upon standing up, high blood pressure, itching, loss of identity, rapid heartbeat, ringing in the ears, trauma, twitching, urinary problems, weight loss
PAROXETINE ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: visual impairment, muscle paralysis, bradycardia, angioedema, anaphylactoid reactions, bronchospasm, keratoconjunctivitis, pancreatitis, proteinuria, peptic ulcer, hematemesis, GI obstruction, ileus, akinesia, torticollis, coma, myelitis, seizures, myocardial infarction, stroke, atrial fibrillation, heart failure, pulmonary embolism, thrombosis, erythema nodosum, erythema multiforme, exfoliative dermatitis, pulmonary fibrosis, pulmonary edema, hearing loss, retinal hemorrhage, ocular hypertension, ocular hemorrhage, oliguria, epididymitis, hyperkalemia, laryngospasm, Guillain-Barre syndrome, SIADH, vasculitis, agranulocytosis, aplastic anemia, GI bleeding, pancytopenia, hemolytic anemia, ventricular fibrillation, torsade de pointes, ventricular tachycardia, pulmonary hypertension, toxic epidermal necrolysis, Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), optic neuritis, hepatic necrosis, porphyria, renal failure (unspecified), serotonin syndrome, bone fractures, teratogenesis, neonatal abstinence syndrome, persistent pulmonary hypertension of the newborn
Moderate: ejaculation dysfunction , constipation, impotence (erectile dysfunction), peripheral vasodilation, blurred vision, hypertonia, myoclonia, chest pain (unspecified), palpitations, dysuria, amnesia, memory impairment, hypertension, sinus tachycardia, myopathy, teeth grinding (bruxism), stomatitis, colitis, dysphagia, melena, gastritis, hemorrhoids, dyskinesia, dystonic reaction, nystagmus, ataxia, neuropathic pain, confusion, migraine, lymphadenopathy, anemia, leukopenia, eosinophilia, hematoma, orthostatic hypotension, hypotension, supraventricular tachycardia (SVT), angina, edema , contact dermatitis, atopic dermatitis, dyspnea, conjunctivitis, elevated hepatic enzymes, vaginitis, urinary retention, pyuria, urinary incontinence, cystitis, myasthenia, peripheral edema, oral ulceration, sialadenitis, gingival hyperplasia, glossitis, cholelithiasis, fecal incontinence, esophagitis, choreoathetosis, dysarthria, trismus, hyperalgesia, hyperreflexia , meningitis, aphasia, neuritis, hyponatremia, thrombocytopenia, lymphopenia, prolonged bleeding time, lymphocytosis, bundle-branch block, phlebitis, candidiasis, furunculosis, skin ulcer, bullous rash, hemoptysis, dysphonia, amblyopia, blepharitis, hyperacusis, cataracts, exophthalmos, photophobia, hyperbilirubinemia, jaundice, hepatitis, vaginal bleeding, prostatitis, nephrolithiasis, flank pain, tetany, hypothyroidism, hyperthyroidism, diabetes mellitus, goiter, hyperglycemia, hypoglycemia, hypercalcemia, hypokalemia, hypercholesterolemia, hypocalcemia, gout, dehydration, hyperphosphatemia, osteoporosis , withdrawal, akathisia, bleeding, platelet dysfunction, pneumonitis, hepatomegaly, hyperprolactinemia, priapism, galactorrhea, hematuria, osteopenia, growth inhibition
Mild: headache, nausea, insomnia, drowsiness, asthenia, diarrhea, xerostomia, dizziness, libido decrease, tremor, hyperhidrosis, anorexia, orgasm dysfunction, sinusitis, infection, abdominal pain, flatulence, dyspepsia, yawning, dysmenorrhea, back pain, myalgia, malaise, fatigue, lethargy, appetite stimulation, paresthesias, pharyngitis, rhinitis, weight gain, vomiting, rash. increased urinary frequency, chills, cough, fever, dysgeusia, arthralgia, gingivitis, dental pain, eructation,
gastroesophageal reflux, weight loss, hyperkinesis, vertigo, hypoesthesia, purpura, leukocytosis, ecchymosis, syncope, photosensitivity, acne vulgaris, urticaria, xerosis, alopecia, hyperventilation, laryngitis, ocular pain, mydriasis, otalgia, amenorrhea, libido increase, menorrhagia, urinary urgency, polyuria, nocturia, polydipsia, dental caries, tongue discoloration, hyporeflexia, pallor, hypothermia, skin discoloration, seborrhea, vesicular rash, maculopapular rash, hirsutism, hiccups, diplopia, parosmia, ptosis, gynecomastia, leukorrhea, mastalgia, breast enlargement, breast discharge, pelvic pain, muscle cramps, pruritus, tinnitus, restless legs syndrome (RLS), petechiae
PAROXETINE BOXED WARNINGS: per PDR:
Children, growth inhibition, suicidal ideation
Paroxetine is not FDA-approved for use in children and adolescents less than 18 years of age. According to the FDA, there are 3 well-controlled trials that have shown paroxetine is no more effective than placebo for the treatment of depression in pediatric patients. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients with MDD and other psychiatric disorders (OCD, social anxiety disorder). A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment of SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). In a meta-analysis conducted by the manufacturer in adult patients with and without psychiatric disorders, a higher frequency of suicidal behavior occurred in young adults and adults treated with paroxetine compared with placebo. This difference was statistically significant; however, as the number of events were small, these data should be interpreted with caution. All of the reported events of suicidal behavior in the adult patients with depression were non-fatal suicide attempts, and the majority of these attempts (8 of 11) were in younger adult patients. The possibility of a suicide attempt is inherent in all patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder such as OCD. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with paroxetine. In patients who exhibit changes in symptoms, worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy; monitor height and weight periodically. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving paroxetine.
PAROXETINE TECHNICAL DATA AND REFERENCES
Per the FDA:
If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION: Discontinuation of Treatment With PAXIL, for a description of the risks of discontinuation of PAXIL).
Discontinuation of Treatment With PAXIL:
Symptoms associated with discontinuation of PAXIL have been reported (see PRECAUTIONS: Discontinuation of Treatment With PAXIL). Patients should be monitored for these symptoms when discontinuing treatment, regardless of the indication for which PAXIL is being prescribed. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with Your physician to help you with your drug withdrawal process and with his or her consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..